Novel crystalline forms of a factor XA inhibitor

Details for Australian Patent Application No. 2002211425 (hide)

Owner Aventis Pharmaceuticals, Inc.

Inventors Woodward, Rick G; Teager, David S.

Agent Watermark

Pub. Number AU-B-2002211425

PCT Pub. Number WO02/28836

Priority 0108903.6 10.04.01 GB; 60/238,316 05.10.00 US

Filing date 4 October 2001

Wipo publication date 15 April 2002

Acceptance publication date 2 March 2006

International Classifications

C07D 213/89 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/4412 (2006.01) - having oxo groups directly attached to the heterocyclic ring

A61P 7/00 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

2 March 2006 Application Accepted

  Published as AU-B-2002211425

29 June 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002211426

2002211424